NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $39.81 +0.06 (+0.15%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$39.65 -0.16 (-0.41%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNTA alerts:Sign Up Key Stats Today's Range$39.74▼$39.8550-Day Range$25.94▼$39.8652-Week Range$10.95▼$40.26Volume1.75 million shsAverage Volume1.30 million shsMarket Capitalization$5.94 billionP/E RatioN/ADividend YieldN/APrice Target$40.70Consensus RatingHold Company Overview Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain. Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders. Each affiliated research unit is advancing one or more drug candidates through discovery, preclinical studies and clinical trials. By maintaining strategic agility within its autonomous project teams, Centessa seeks to optimize development timelines and increase the probability of regulatory success. The company was formed in 2021 through an investment consortium and completed its initial public offering via a business combination with Narwhal Acquisition Corp. in early 2022. Headquartered in Cambridge, U.K., Centessa maintains a significant presence in the United States, with research and development sites located in key biotech hubs. This transatlantic footprint enables collaboration with leading academic institutions and access to diverse clinical trial networks. Under the leadership of Chief Executive Officer Knut Brundin, Centessa Pharmaceuticals draws on decades of industry experience to guide its strategic vision. The management team is complemented by veteran drug developers, regulatory experts and academic advisors, all committed to advancing novel therapies from laboratory research to patient care. AI Generated. May Contain Errors. Read More Centessa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreCNTA MarketRank™: Centessa Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 742nd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingHold Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on no strong buy ratings, 4 buy ratings, 9 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Centessa Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCentessa Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Centessa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to decrease in the coming year, from ($1.65) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 12.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.96% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 19.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for CNTA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,424,535.00 in company stock.Percentage Held by Insiders4.09% of the stock of Centessa Pharmaceuticals is held by insiders.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTA Stock News HeadlinesAre CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?May 12, 2026 | prnewswire.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of "Hold" from AnalystsMay 12, 2026 | americanbankingnews.comSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plastics, fuels, metals, textiles, and industrial commodities. The company's Digital Material Passport technology targets verified origin, recycled content, and lifecycle data across global supply chains - a market growing more compliance-driven by the day. As governments tighten recycled-content reporting standards, SMX is positioning itself at the center of that shift.May 22 at 1:00 AM | Smallcaps Daily (Ad)Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTAMay 11, 2026 | businesswire.comCentessa Pharmaceuticals (CNTA) Projected to Post Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comIs It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?May 4, 2026 | finance.yahoo.comCentessa Pharmaceuticals plc (CNTA)May 1, 2026 | finance.yahoo.comWells Fargo downgrades Centessa Pharmaceuticals plc - Depositary Receipt (CNTA)April 21, 2026 | msn.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $25.01 at the start of the year. Since then, CNTA stock has increased by 59.2% and is now trading at $39.81. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.14. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $314 million in an initial public offering on Friday, May 28th 2021. The company issued 16,500,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Centessa Pharmaceuticals' top institutional shareholders include Janus Henderson Group PLC (2.34%), Bank of America Corp DE (1.29%), Maverick Capital Ltd. (1.24%) and First Light Asset Management LLC (1.05%). Insiders that own company stock include Antoine Yver, Arjun Goyal, David M Chao, Saurabh Saha, Mario Alberto Accardi, Tia L Bush, Gregory M Weinhoff, Harris Rotman, Karen M Anderson and Iqbal J Hussain. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Centessa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings5/05/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CNTA's financial health is in the Green zone, according to TradeSmith. CNTA has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year Founded2021Price Target and Rating Average Price Target for Centessa Pharmaceuticals$40.70 High Price Target$62.00 Low Price Target$30.00 Potential Upside/Downside+2.2%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$197.53 million Net MarginsN/A Pretax Margin-1,304.75% Return on Equity-60.37% Return on Assets-44.17% Debt Debt-to-Equity Ratio0.23 Current Ratio9.53 Quick Ratio9.53 Sales & Book Value Annual Sales$15 million Price / Sales396.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book12.17Miscellaneous Outstanding Shares149,230,000Free Float143,125,000Market Cap$5.94 billion OptionableOptionable Beta1.13 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CNTA) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...Smallcaps Daily | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
